8 completed, 1 unknown. 9 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 8, Unknown 1 |
| Phase 3 | 2 | Completed 1, Unknown 1 |
Follow Impetigo: new trials by email Literature Review of Impetigo trials Research Report on Impetigo
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study Evaluating the Safety, Tolerability, PK, and Activity of Topical ATx201 Gel in Outpatients With Impetigo ATx201, ATx201 GEL Vehicle - Impetigo | Phase 2 | Completed | UNION therapeutics | 210 | 2018-02-23 | 2018-07-31 |
| A Phase II Study to Evaluate the Efficacy and Safety of Two Doses of LTX-109 in Impetigo LTX-109 1 %, LTX-109 2 %, Placebo gel - Non-bullous Impetigo | Phase 2 | Completed | Lytix Biopharma AS | 210 | 2013-02-01 | 2014-04-28 |
| Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo Experimental: CD07223 1.5 % Topical Gel BID, Experimental: CD07223 1.5% Topical Gel TID, Placebo Comparator: CD07223 vehicle gel BID - Impetigo | Phase 2 / Phase 3 | Completed | NovaBay Pharmaceuticals, Inc. | 328 | 2012-08-01 | 2014-08-12 |
| Citriodiol® and Impetigo p-menthane-3,8-diol oil - Impetigo | Phase 2 / Phase 3 | Unknown | Royal North Shore Hospital | 30 | 2012-07-01 | 2012-06-20 |
| A Study to Evaluate Safety, Tolerability and Efficacy of Lytixar™ (LTX-109) on Uncomplicated, Gram-positive, Skin Infection LTX-109 - Gram-positive, Skin Infections, Mild Eczema/Dermatoses | Phase 2 | Completed | Lytix Biopharma AS | 24 | 2010-09-01 | 2011-02-16 |
| Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Impetigo Patients Topical Minocycline Foam FXFM244 - Impetigo | Phase 2 | Completed | Vyne Therapeutics Inc. | 32 | 2010-08-01 | 2013-12-10 |
| Safety and Efficacy of Topical NVC-422 Gel in Impetigo NVC-422 - Impetigo | Phase 2 | Completed | NovaBay Pharmaceuticals, Inc. | 129 | 2009-08-01 | 2011-06-07 |
| The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo 2% TD1414 Cream - Secondarily Infected Traumatic Lesions (SITL), Impetigo | Phase 2 | Completed | LEO Pharma | 20 | 2008-12-01 | 2025-03-13 |
| Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL) TD1414 2% cream, Bactroban® (mupirocin) 2% cream - Impetigo, Secondarily Infected Traumatic Lesions | Phase 2 | Completed | LEO Pharma | 773 | 2008-02-01 | 2025-03-12 |
Cellulitis (1) · Dermatitis, Atopic (1) · Skin Diseases (1) · cyclopia sequence (1)
Bacterial Infections (9) · Bacterial Infections and Mycoses (9) · Gram-Positive Bacterial Infections (9) · Infections (9) · Skin Diseases, Bacterial (9) · Skin Diseases, Infectious (9) · Skin and Connective Tissue Diseases (9) · Staphylococcal Infections (9) · Staphylococcal Skin Infections (9) · Streptococcal Infections (9) · Skin Diseases (8) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Connective Tissue Diseases (1) · Dermatitis (1) · Genetic Diseases, Inborn (1)
L-arginyl-2,5,7-tris(1,1-dimethylethyl)-L-tryptophyl-N-(2-phenylethyl)-L-argininamide (1) · Mupirocin (1) · NVC-422 (1) · terpin (1)
LEO Pharma (2) · Lytix Biopharma AS (2) · NovaBay Pharmaceuticals, Inc. (2) · Royal North Shore Hospital (1) · UNION therapeutics (1) · Vyne Therapeutics Inc. (1)
South Africa (3) · United States (3) · Dominican Republic (2) · Australia (1) · Hungary (1) · Israel (1)
Almena L Free, MD (1) · Daisy M Blanco, MD (1) · Daisy M. Blanco, MD (1) · Josefina Fernandez, MD (1) · Kenneth D. Krantz, MD, PhD (1) · Lajos Kemeny, DSc, Prof (1) · Philippe Prokocimer, MD (1) · Terry Jones, MD (1)